Eagan, Minnesota–(February 8, 2024) – Dynatronics Corporation (NASDAQ: DYNT) (“Dynatronics” or the “Company”), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today reported financial results for its second quarter of fiscal year 2024 ended December 31, 2023.
CEO Commentary
“We continue to make progress on achieving our sales goals and finding our path to positive EBITDA,” said Brian Baker, Chief Executive Officer of Dynatronics. “We continue our focus on our fiscal year 2024 operating plan and making progress on our strategic priorities with encouraging results. Our commercial team has been working closely with our strategic customers to identify new product opportunities. We have been aggressively developing, manufacturing, and building stock to support customer demand. Our plan is to manage a limited launch of new products in the third quarter fiscal year 2024, and full launch in the fourth quarter fiscal year 2024. We are excited about the potential incremental revenue these products can contribute to our business.”
Key Financial Results
Q2 Fiscal Year ’24 Financial Highlights
Note: All financials referenced in this release are in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) and comparisons in this release are to the same period in the prior year unless otherwise noted.
- Total net sales of $8.2 million.
- Gross profit margin of 22.3%.
- Net loss of $1.0 million compared to net loss of $0.8 million in Q2 fiscal year ’23.
Notable Balance Sheet Highlights
- Net cash of $0.6 million unchanged from $0.6 million as of June 30, 2023.
- As of December 31, 2023, $1.9 million drawn, with an additional $2.5 million available on working capital asset-based line of credit established on August 1, 2023.
- Proceeds from line of credit reduced accounts payable and accrued expenses by $0.7 million and funded $0.8 million of prepaid expenses.
Guidance for Fiscal Year ’24
Dynatronics estimated net sales to be in the lower range of revenue estimates of $34 to $37 million, due to slower demand in the rehabilitation space. The Company expects the distribution of net sales across the quarters in fiscal year ’24 to align with historical trends, which are highest in the first quarter, lower in the second and third quarters, with a bounce back in the fourth quarter.
The Company is continuing its recent practice of not providing gross margin guidance given the recent reductions in revenue and operating costs.
The Company reaffirmed its guidance on selling, general, and administrative expenses that are anticipated to be 29% to 33% of net sales in fiscal year ’24.
The Company’s financial guidance for fiscal year ’24 is subject to the risks identified in its safe harbor notification below. The Company continues to expect volatility due to the challenges related to the broader economic environment, including competitive pressures, inflationary pressures, supply chain disruptions, extended handling times and delays or disruption in procedure volume. Dynatronics also expects some ongoing volatility from the Company’s business optimization.
Conference Call Q2 Fiscal Year ’24 Results
The Company will hold a conference call, consisting of prepared remarks by management, and a question-and-answer session with analysts, at 8:00 AM ET on Thursday, February 8, 2024, to review its fiscal year ’24 second quarter results.
Interested persons may access the live conference call by dialing 1-800-319-4610 (U.S./Canada callers) or +1-604-638-5340 (international callers). It is recommended that participants call or login 10 minutes ahead of the scheduled start time to ensure proper connection. An audio replay will be available one hour after the live call until Midnight on February 15, 2024, by dialing 1-855-669-9658 (U.S./Canada callers) or +1-604-674-8052 (international callers), using replay access code 0667.
About Dynatronics Corporation
Dynatronics is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures and sells a broad range of products for clinical use in physical therapy, rehabilitation, orthopedics, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals. The Company’s products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Solaris™, Hausmann®, and PROTEAM™, among others. More information is available at www.dynatronics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Those statements include references to the Company’s expectations and similar statements. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our statements regarding the Company’s planned product launches, expected overall performance, expectations regarding net sales, distribution of net sales, and selling general and administrative costs in fiscal year 2024, and uncertainties related to the broader economic environment, including higher raw material, delivery and shipment costs, supply chain disruptions, extended handling times and delays or disruption in procedure volume and volatility resulting from continued execution of the Company’s business optimization strategy. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in the Company’s annual, quarterly, and other reports filed with the Securities and Exchange Commission. Dynatronics does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.
Summary Financial Results
Following is a summary of operating results for the periods ended December 31, 2023, the balance sheet highlights at December 31, 2023 and cash flow for periods ended December 31, 2023.
Summary Selected Financial Data
Statements of Operations Highlights
In thousands, except share and per share amounts
| Quarter Ended | Six Months Ended | |||||||||||
| December 31, | December 31, | |||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||
| Net sales | $ | 8,151 | $ | 10,882 | $ | 17,503 | $ | 22,936 | ||||
| Cost of sales | 6,331 | 7,820 | 13,377 | 16,231 | ||||||||
| Gross Profit | 1,820 | 3,062 | 4,126 | 6,705 | ||||||||
| 22.3% | 28.1% | 23.6% | 29.2% | |||||||||
| Selling, general and administrative expenses | 2,722 | 3,862 | 5,267 | 7,980 | ||||||||
| Other (expense) income, net | (109) | (41) | (201) | (72) | ||||||||
| Net income (loss) | $ | (1,011) | $ | (841) | $ | (1,342) | $ | (1,347) | ||||
| Preferred stock dividend, in common stock, issued or to be issued | (191) | (173) | (388) | (343) | ||||||||
| Net income (loss) attributable to common stockholders | $ | (1,202) | $ | (1,014) | $ | (1,730) | $ | (1,690) | ||||
| Net loss attributable to common stockholders per | ||||||||||||
| common share – basic and diluted | $ | (0.27) | $ | (0.27) | $ | (0.39) | $ | (0.45) | ||||
| Weighted-average common shares outstanding – basic and | ||||||||||||
| diluted | 4,524,965 | 3,794,333 | 4,393,279 | 3,750,930 | ||||||||
Balance Sheet Highlights
In thousands
| December 31, 2023 | June 30, 2023 | |||||
| Cash and cash equivalents and restricted cash | $ | 555 | $ | 553 | ||
| Trade accounts receivable, net | 3,738 | 3,722 | ||||
| Inventories, net | 6,753 | 7,403 | ||||
| Prepaids & other | 1,849 | 741 | ||||
| Total current assets | 12,895 | 12,419 | ||||
| Non-current assets | 16,404 | 17,644 | ||||
| Total assets | $ | 29,299 | $ | 30,063 | ||
| Accounts payable | $ | 3,975 | $ | 4,530 | ||
| Accrued payroll and benefits expense | 603 | 878 | ||||
| Accrued expenses | 1,094 | 891 | ||||
| Other current liabilities | 1,605 | 1,642 | ||||
| Line of credit | 1,897 | – | ||||
| Total current liabilities | 9,174 | 7,941 | ||||
| Non-current liabilities | 4,595 | 5,265 | ||||
| Total liabilities | 13,769 | 13,206 | ||||
| Stockholders’ equity | 15,530 | 16,857 | ||||
| Total liabilities and stockholders’ equity | $ | 29,299 | $ | 30,063 |
Cash Flow Highlights
In thousands
| Six Months Ended | ||||||
| December 31 | ||||||
| 2023 | 2022 | |||||
| Net loss | $ | (1,342) | $ | (1,347) | ||
| Depreciation and amortization | 652 | 682 | ||||
| Stock-based compensation | 15 | 86 | ||||
| (Gain) loss on sale of property and equipment | 41 | – | ||||
| Receivables | (16) | 185 | ||||
| Inventory | 650 | 1,325 | ||||
| Prepaid and other assets | (827) | 134 | ||||
| Accounts payable, accrued expenses, and other liabilities | (697) | (774) | ||||
| Net cash provided by (used in) operating activities | (1,524) | 291 | ||||
| Net cash used in investing activities | (230) | (126) | ||||
| Payments on non-current liabilities | 1,756 | (181) | ||||
| Net cash used in financing activities | 1,756 | (181) | ||||
| Net change in cash and cash equivalents | 2 | (16) | ||||
| Cash and cash equivalents at beginning of the period | 553 | 701 | ||||
| Cash and cash equivalents at end of the period | $ | 555 | $ | 685 | ||
Contact:
Dynatronics Corporation
Investor Relations
ir@dynatronics.com
For additional information, please visit: www.dynatronics.com.
Connect with Dynatronics on LinkedIn
SOURCE: Dynatronics Corporation
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/197011
